Jpmorgan Chase & CO Neuro Pace Inc Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Neuro Pace Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 43,792 shares of NPCE stock, worth $446,678. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43,792
Previous 64,826
32.45%
Holding current value
$446,678
Previous $725,000
25.79%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding NPCE
# of Institutions
93Shares Held
24.8MCall Options Held
1.8KPut Options Held
300-
Orbimed Advisors LLC San Diego, CA3.41MShares$34.7 Million1.3% of portfolio
-
Polar Capital Holdings PLC London, X02.97MShares$30.3 Million0.24% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.61MShares$26.6 Million2.65% of portfolio
-
Morgan Stanley New York, NY2.53MShares$25.8 Million0.0% of portfolio
-
First Light Asset Management, LLC Edina, MN1.58MShares$16.2 Million2.5% of portfolio
About NeuroPace Inc
- Ticker NPCE
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 24,846,900
- Market Cap $253M
- Description
- NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and ena...